Primeval Labs, LLC – Trademark Portfolio
Entity Type: 16
Primeval Labs, LLC holds 29 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 28 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 15 trademarks are registered and 5 are pending. Notable registered marks include DIA, DÍA, ISOLIT, APESH*T, and EAA MAX. The owner is based in Dallas, TX.
3010 LBJ Freeway, Suite 1200
Dallas, TX 75234
Showing of trademarks Trademarks
Trademark Classifications
Primeval Labs, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Beers; mineral and aerated waters and other non-alcoholic beverages; fruit beverages
Frequently Asked Questions
How many trademarks does Primeval Labs, LLC have?
Primeval Labs, LLC has 29 U.S. trademarks filed with the USPTO. Of these, 15 registered, 5 pending, 9 abandoned.
What trademark classes does Primeval Labs, LLC file in?
Primeval Labs, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 32 (Light Beverages). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Primeval Labs, LLC's most well-known trademarks?
Primeval Labs, LLC's registered trademark portfolio includes well-known marks such as DIA, DÍA, ISOLIT, APESH*T, and EAA MAX. These are among 15 currently registered trademarks in the portfolio.
What is Primeval Labs, LLC's trademark registration success rate?
Primeval Labs, LLC has a 63% trademark registration rate, with 15 out of 24 resolved applications resulting in successful registration. Currently, 5 applications are pending review.